Study	Threshold	TP	FP	FN	TN	Se [95% CI]	Sp [95% CI]
Nakai 2022	9.2	19	91	9	400	0.68 [0.49, 0.82]	0.81 [0.78, 0.85]
Pons 2020	20	13	199	12	348	0.52 [0.33, 0.70]	0.64 [0.60, 0.68]
Rinaldi 2019	27.8	25	78	10	144	0.71 [0.55, 0.84]	0.65 [0.58, 0.71]
Wang 2016	12	12	28	9	326	0.57 [0.37, 0.76]	0.92 [0.89, 0.94]
Liu 2023	12	33	241	7	184	0.82 [0.68, 0.91]	0.43 [0.39, 0.48]
	13	27	213	13	213	0.68 [0.52, 0.80]	0.50 [0.45, 0.55]
	10	38	348	2	77	0.95 [0.83, 0.99]	0.18 [0.15, 0.22]
Kuo 2022	11	21	244	7	424	0.75 [0.57, 0.87]	0.63 [0.60, 0.67]
Morisco 2021	20	1	166	25	375	0.04 [0.01, 0.19]	0.69 [0.65, 0.73]
Kim 2023	9.2	31	508	3	706	0.91 [0.77, 0.97]	0.58 [0.55, 0.61]
	10	31	471	3	743	0.91 [0.77, 0.97]	0.61 [0.58, 0.64]
	11	30	403	4	811	0.88 [0.73, 0.95]	0.67 [0.64, 0.69]
	12	28	356	6	858	0.82 [0.66, 0.92]	0.71 [0.68, 0.73]
	13	27	320	7	894	0.79 [0.63, 0.90]	0.74 [0.71, 0.76]
	20	20	157	14	1057	0.59 [0.42, 0.74]	0.87 [0.85, 0.89]
	27.8	11	61	23	1153	0.32 [0.19, 0.49]	0.95 [0.94, 0.96]



A

Study	Threshold	TP	FP	FN	TN	Se [95% CI]	Sp [95% CI]
Nakai 2022	8.4	23	23	7	360	0.77 [0.59, 0.88]	0.73 [0.69, 0.77]
Pons 2020	10	21	21	4	216	0.84 [0.65, 0.94]	0.39 [0.35, 0.44]
Liu 2023	10	30	30	10	233	0.75 [0.60, 0.86]	0.55 [0.50, 0.59]
	9.5	30	30	10	225	0.75 [0.60, 0.86]	0.53 [0.48, 0.58]
Kuo 2022	11	21	21	7	425	0.75 [0.57, 0.87]	0.64 [0.60, 0.67]
Ogawa 2020	10	11	11	3	188	0.79 [0.52, 0.92]	0.67 [0.61, 0.72]
Kim 2023	8.4	26	26	8	833	0.76 [0.60, 0.88]	0.69 [0.66, 0.71]
	9.5	26	26	8	892	0.76 [0.60, 0.88]	0.73 [0.71, 0.76]
	10	26	26	8	912	0.76 [0.60, 0.88]	0.75 [0.73, 0.77]
	11	25	25	9	971	0.74 [0.57, 0.85]	0.80 [0.78, 0.82]



B

Supplementary Figure 2. Forest plots of studies included in the diagnostic accuracy analysis for the prediction of HCC using VCTE measured at (A) pre-treatment and (B) after SVR. HCC, hepatocellular carcinoma; VCTE, vibration-controlled transient elastography; SVR, sustained virological response.